Company intelligence / Profile preview

Fourth Frontier

Austin, Texas, United Statesfourthfrontier.com ↗

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

The company's flagship product "Frontier X Plus" received FDA 510(k) clearance and offers continuous single-channel ECG monitoring via a chest-worn device. It enables early detection of arrhythmias and provides AI-powered heart rhythm analysis. The product has seen significant adoption among healthcare professionals and patients globally. No clinical trial results are published; the focus is on real-world use.

Therapeutic areas: Cardiovascular
Modalities: DeviceDigital health platformAI-powered heart rhythm analysis
Industry: Physiological Monitoring

Partnerships

None specifically disclosed; trusted by leading cardiologists and research centers globally

Beyond the preview

Go deeper on Fourth Frontier.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fourth Frontier.

Explore the full profile